Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given an average rating of “Moderate Buy” by the twenty-three analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $1,099.55.

A number of equities analysts have recently commented on REGN shares. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Wolfe Research initiated coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after buying an additional 61,277 shares during the period. International Assets Investment Management LLC increased its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Regeneron Pharmaceuticals by 12.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after buying an additional 96,266 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.9 %

REGN opened at $738.00 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $735.95 and a 52 week high of $1,211.20. The business’s 50 day moving average is $945.07 and its two-hundred day moving average is $1,027.02. The firm has a market cap of $81.10 billion, a price-to-earnings ratio of 18.26, a price-to-earnings-growth ratio of 2.87 and a beta of 0.15.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.